Skip to main content

Antonio Llombart-Cussac, MD, PhD

Antonio Llombart-Cussac MD, PhD
Conference Coverage
12/07/2023
Antonio Llombart-Cussac MD, PhD, discussed extended follow-up results from the phase 2 PARSIFAL study combining the CDK4/6 inhibitor palbociclib with either fulvestrant or letrozole.
Antonio Llombart-Cussac MD, PhD, discussed extended follow-up results from the phase 2 PARSIFAL study combining the CDK4/6 inhibitor palbociclib with either fulvestrant or letrozole.
Antonio Llombart-Cussac MD, PhD,...
12/07/2023
Oncology